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Abstract: Melphalan combined with prednisone (MP) has long been the historical treatment of 
reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem 
cell transplantation, and is still the backbone of new regimens that include the new era of novel 
agents. Melphalan–prednisone–thalidomide (MPT) and melphalan–prednisone–bortezomib 
(Velcade®, MPV), proved superior to MP, currently appear to be the treatments of choice for 
this population. In the near future melphalan–prednisone–lenalidomide (Revlimid®, MPR) will 
also provide a third therapeutic option (MPT, MPV, and MPR), in elderly multiple myeloma, 
eventually. These options could lead to more personalized treatment approaches, based on 
patient comorbidities, as the three novel agents have somewhat different toxicity proﬁ  les. 
Dexamethasone-based regimen is another option and questions regarding the relative efﬁ  cacy 
of melphalan-based versus low-dose dexamethasone-based regimens will require randomized 
phase III trials. More intensive approaches with new drug combinations or with the incorporation 
of polyethylene glycolated (PEGylated) liposomal doxorubicin will also require additional 
studies. Additionally, the important issue of maintenance treatment needs to be further inves-
tigated. These new and emerging therapies offer multiple effective treatment options for MM 
patients and greatly enhanced treatment strategies for clinicians.
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Introduction
Multiple myeloma (MM) is the second most common hematologic malignancy 
and a disease of the elderly.1 The annual age-speciﬁ  c incidence of MM increased 
considerably with age, up to  40/100,000 for persons  80 years of age in some 
series. The median age at diagnosis for multiple myeloma is 71 and around 65% of all 
new cases of MM will be older than 65 years. The number of older patients with this 
disease is expected to rise over time as a consequence of the increased life expectancy 
of the normal population.2 Myeloma is the cause of death in 75% of patients older 
than 65 years with MM.
The recent report from the Surveillance, Epidemiology, and End Results (SEER) 
Program in patients with myeloma pointed out the gap between young and elderly 
patients.3 From 1990–1992 to 2002–2004, a major improvement of long-term survival 
had been achieved in younger patients. In contrast, no improvement in survival was 
observed in patients over 70 years of age and only a modest improvement in patients 
between 60 and 69 years of age.
Diverse factors including comorbidity, lower performance status, decreased 
physiologic reserve, and potential undertreatment contribute to this poor outcome, 
although supportive care of these patients has improved in recent years.4,5 However, the 
concerted action of speciﬁ  c myeloma therapeutics, including most recent progresses 
in novel agents, and supportive therapies can signiﬁ  cantly improve the quality of life Biologics: Targets & Therapy 2009:3 100
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of myeloma patients.6 At the time of diagnosis, patients with 
MM can be divided into those who either are asymptomatic 
(approximately 25% of patients) or symptomatic, these 
latter requiring a prompt chemotherapy-based intervention. 
High-dose melphalan with autologous stem cell trans-
plantation (ASCT) is considered the standard of care for 
patients younger than 65 years of age. Recent studies have 
suggested that ASCT is safe in some patients over the age 
of 65, including some rare patients over the age of 70, but it 
does not represent routine practice.7–9 Combination chemo-
therapy with melphalan and prednisone (MP) has been used 
since the 1960s and, as recently as two years ago, remained 
the most widely accepted treatment option for elderly 
patients ineligible for high-dose therapy.10–12 More complex 
combinations with alkylating agents have been substituted 
but often with added toxicity and inconvenience and no 
survival advantage over MP.13 Dexamethasone (Dex)-based 
regimens have provided other options.12,14,15 Overall, two 
different backbones have been used for the development of 
new combinations; MP, mainly in Europe, and Dex, more 
frequently in North America.
Melphalan–prednisone-based 
combinations
MP + thalidomide
In the wake of the activity of thalidomide noted in the late 
1990s against relapsed/refractory myeloma,16 the drug was 
then rapidly moved up to the ﬁ  rst line, in combination with 
MP. Following promising results achieved in a phase II 
study,17 the MPT combination was evaluated against MP 
in several phase III randomized studies as a front-line 
therapeutic in elderly myeloma patients. The results of two 
studies, one from the GIMEMA (Groupe Italiano Malattie 
Ematologiche dell’Adulto, 255 patients) and one from 
the Intergroupe Francophone du Myélome (IFM; IFM 99-06, 
447 patients) are now available.18–20 Two additional trials have 
recently reported results from phase III placebo-controlled 
studies comparing MPT with MP-placebo: one from the IFM 
(IFM 01-01, 232 patients) and the other from the Nordic 
Myeloma Study Group (NMSG; 362 patients).21,22 Other 
studies are ongoing from the HOVON and GIMEMA study 
groups.23,24
Trial designs
In the IFM99-06 trial, all patients were between 65 and 
75 years of age.19 The MP regimen consisted of twelve 
6-week cycles with melphalan 0.25 mg/kg and prednisone 
2 mg/kg/day, days 1–4. In the MPT arm, the same MP regimen 
was delivered plus thalidomide at the maximum tolerated dose 
not exceeding 400 mg daily. The thalidomide was stopped at 
the end of MP (no maintenance phase). The IFM 99-06 trial 
also incorporated a third arm with standard induction : 2 cycles 
of vincristine–doxorubicine–dexamethasone (VAD), cyclo-
phosphamide 3 g/m2 and stem cell mobilization and interme-
diate dose melphalan 100 mg/m2 (MEL100) with stem cell 
transplantation (2 consecutive cycles of MEL100). The study 
was therefore the ﬁ  rst and only study to evaluate thalidomide 
in combination with standard MP against both standard MP 
alone and stem cell transplantation with a reduced intensity 
conditioning regimen.
In the GIMEMA trial comparing MP with MPT, patients 
were between 60 and 85 years of age.18,25 The MP regimen 
consisted of six 4-week cycles with melphalan 4 mg/m2 days 
1–7. The MPT regimen consisted of the same MP regimen 
plus thalidomide 100 mg daily until progression. The primary 
endpoint was response rate and event-free survival.
The IFM 01-01 double-blind trial, comparing MP plus 
placebo with MPT, was remarkable in that it was exclu-
sively devoted to patients over the age of 75 (median age 
78.5 years, one third of patients over 80).21 Even though 
these patients represent more than 20% of MM patients, 
there are rarely considered for enrolment in clinical trials. As 
in the IFM 99-06, twelve 6-week cycles of MP were given 
but with a lower dose of melphalan (0.2 mg/kg days 1–4). 
Thalidomide was given at 100 mg daily until the end of MP 
(no maintenance).
In the NMSG trial, mean age was 75 years (49–92) 
the MP regimen consisted of 6-week cycles until plateau 
phase with melphalan 0.25 mg/kg. Thalidomide was 
started at 200 mg daily and escalated to 400 mg daily. 
Patients also received thalidomide maintenance treat-
ment in plateau phase at 200 mg daily.22 In this study, as 
well as in IFM studies, the primary endpoint was overall 
survival.
Study results
In the first two published phase III studies (GIMEMA 
and IFM 99–06), the superiority of MPT over MP was 
clearly demonstrated on the basis of response, including 
complete response (CR), and progression-free survival 
(Table 1).18–20 MPT response results were concordant with 
13% and 15.5% CR rates in the GIMEMA and IFM 99-06 
studies, respectively, and an identical 76% overall response 
rate. In the IFM 01-01 study, response results of MPT 
arm were slightly inferior but still signiﬁ  cantly superior to 
those of MP, with a 61% response rate and a 7% CR rate.21 Biologics: Targets & Therapy 2009:3 101
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Median progression-free survival times with MPT were 
similar in all three studies, ranging from 24 to 27.5 months. 
Concerning overall survival, only a nonsigniﬁ  cant survival 
advantage was noted with MP arm in the GIMEMA study. 
In both IFM studies, the progression-free survival advan-
tage observed with MPT translated into a signiﬁ  cant overall 
survival advantage. In the Nordic Study, the addition of 
thalidomide to MP resulted in a signiﬁ  cant advantage in 
terms of response rate and time to progression compared 
with MP.22 However, these favorable results did not translate 
into an overall survival advantage. The study was hampered 
by use of higher doses of melphalan and thalidomide in a 
population with a high proportion of patients over 75 years 
of age (mean age 74.5 years) and approximately one third 
of patients with poor performance status (World Health 
Organization [WHO] performance status of 3 or 4 in 30% of 
patients). These characteristics likely contributed to more 
frequent early deaths in the MPT group, especially in the 
oldest patients. Of note effective median or mean durations 
of thalidomide treatment have been somewhat different 
across trials; 8, 11, and 13.5 months (median) in GIMEMA, 
IFM 99-06, and IFM 01-01, respectively, and only 6 months 
(mean) in the NMSG Study.
In the IFM 99-06 study, MPT was also found to be 
superior to the MEL100 strategy with stem cell transplanta-
tion, a strategy with reduced intensity conditioning regimen. 
This result opens the debate on the role of stem cell trans-
plantation in elderly patients in the era of novel agents. In 
patients over the age of 65 years (n = 136), the intensive Total 
Therapy program from the University of Arkansas achieved a 
median overall survival of 60 months with a 13% treatment-
related mortality rate.26 In patients between 65 and 75 years 
of age, the oral MPT from the IFM achieved a median overall 
survival of 52 months with no toxic deaths.
Toxicity
Thalidomide induces a certain amount of hematopoietic and 
nonhematopoietic side effects, and MPT was associated 
with a significantly increased risk of complications in 
phase III trials comparing MP with MPT (Table 2).18,19 
Certain complications are short-term side effects which 
are frequent, reversible, and manageable with appropri-
ate dose reduction such as skin rash, sedation, consti-
pation, sinus bradycardia, hypotension, and fatigue. 
Although teratogenicity should remain in everybody’s 
mind as contraindicating thalidomide administration in 
pregnant women, it is not an issue in elderly women. 
Special recommendations were proposed for men and 
women of childbearing potential.27 Others are time- and 
dose-dependent.28 However, much has been learned in 
the past 8 years about the management of thalidomide-
related toxicities that are no longer a limitation in myeloma 
therapeutics for the majority of patients.29
In either studies from the IFM, a higher incidence of 
grade 3/4 neutropenia was noted but without an increase in 
severe infections.19,21 In contrast, no difference between MP 
and MPT was observed in the GIMEMA study for neutro-
penia, but severe infections were more frequent.18
Deep vein thrombosis (DVT) is a major adverse 
effect of thalidomide therapy, breakdown peripheral 
deep venous thrombosis and pulmonary embolism, the 
latter being of greater risk of morbidity. Its pathogenic 
mechanism has not been clearly established. When 
associated to dexamethasone or chemotherapy, an increased 
Table 1 Comparative response and survival across trials of MPT compared with MP
Trial Regimen N CR (%)  PR (%) PFS (mo) OS (mo)
IFM 99-0619 MPT 125 13 76 27.5 51.6
MP 196 2 35 17.8 33.2
MEL 100 126 18 65 19.4 38.3
GIMEMA20 MPT 129 15.6 76 21.8 45
MP 126 3.7 48 15.5 47.6
IFM 01-0121 MPT 113 7 61 24.1 45.3
MP 116 1 31 19.0 27.7
NMSG Study22 MPT 182 13 57 16 29
MP 175 4 40 14 33
HOVON Study*23 MPT 152 1 63 – –
MP 149 1 47 – –
Notes: For PFS and OS, results are presented in median (months).*Results from interim analysis. MEL100: High-dose melphalan 100 mg/m2.
Abbreviations: N, number of patients; CR, complete response; PR, partial response; PFS, progression-free survival; OS, overall survival.Biologics: Targets & Therapy 2009:3 102
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risk is described. The outcome of DVT when treated only 
by thalidomide is estimated at 5% and increases up to 
15% when thalidomide is associated to either anthracy-
cline or dexamethasone, in absence of any prophylactic 
anticoagulation.30–32 DVT have mainly been reported in the 
ﬁ  rst 6 months of treatment with a large majority in the ﬁ  rst 
3 months when the burden of the tumor is the highest.33 
Following such high incidence of DVT in the initial phases of 
studies, prophylactic anticoagulation was added. Clear throm-
boprophylaxis guidelines have been established for patients 
receiving a monotherapy by thalidomide or a combination 
including this drug when suffering of MM.25 Aspirin, low 
molecular weight heparin (LMWH), or oral warfarin should 
be initiated in all patients starting therapy with thalidomide 
plus dexamethasone and/or chemotherapy.
Peripheral neuropathy is the most common cause of 
thalidomide discontinuation or dose reduction and effects 
15% to 20% of the patients. Moreover elderly patients suffer 
more frequently of this adverse side. Clinic manifestations 
are initially sensory symptoms but can evolve towards 
motor symptoms and autonomic dysfunction. Neuropathy 
is closely related to duration of treatment and cumulative 
dose.34–36 The probability of recovery increases if thalidomide 
is quickly discontinued. Otherwise neuropathic symptoms 
may progress and become irreversible. Practical rules were 
suggested recently by Palumbo in a review on thalidomide: 
no dose modiﬁ  cation if neuropathy is grade I, 50% reduction 
dose if neuropathy is grade II, and interruption thalidomide 
if neuropathy is grade III or above.24
MP + bortezomib (Velcade, MPV)
The introduction of proteasome inhibition with bortezomib 
has expanded treatment options in MM and has signiﬁ  cantly 
improved outcomes for patients with relapsed/refractory 
MM.37,38 The drug was also shown to be synergistic in vitro 
with a wide range of cytotoxic agents, including melphalan.39 
In addition, the combination of bortezomib and melphalan 
was effective in a phase I/II trial.40 Based on these promising 
results, bortezomib was incorporated into the MP regimen 
(MPV) for the treatment of elderly untreated MM patients by 
the spanish group PETHEMA (Programa para el Tratamiento 
de Hemopatias Malignas).41 In total, 60 patients were enrolled 
in this phase I/II study, of whom 53 completed at least one 
cycle of treatment. The median age of patients was 75 years 
(range 65–85 years); 47% of patients were older than 75 years 
and 17% were aged over 80. Patients received four 6-week 
induction cycles (bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 
8, 11, 22, 25, 29, 32) followed by ﬁ  ve 5-week maintenance 
cycles (bortezomib 1.0 or 1.3 mg/m2 on days 1, 8, 15, 22) in 
combination with oral melphalan 9 mg/m2 and prednisone 
60 mg/m2/day. The overall response rate was 89%, including 
32% of patients with immunoﬁ  xation-negative CR and 
an additional 11% with near-CR. The response rate after 
1 cycle of MPV was higher than in historical controls after 
6 cycles of MP (70 versus 42%). After a median follow-up 
of 26 months, median time to progression was 27.2 months, 
median overall survival had not been reached and projected 
3-year overall survival was 85%.42 Time-to-event data in 
the MPV group compared favourably with MP historical 
controls: time to progression, event-free survival and overall 
survival (at 26 months: 27.2 versus 20 months, 23 versus 
16 months, and median not reached versus 26.9 months, 
respectively). MPV was generally well tolerated and the 
majority of adverse events occurred during the ﬁ  rst 2 cycles 
of treatment. The most common grade-3/4 adverse events 
were thrombocytopenia and neutropenia (40%–50%) but 
the frequency of infections was low (16%). Peripheral 
neuropathy and diarrhea were noted in 17% and 16% of 
patients, respectively.
These promising results formed the basis from the 
international VISTA (Velcade as Initial Standard Therapy) 
trial (682 patients; the median age was 71 years with 30% of 
patients aged 75 years), which is so far the largest MP-based 
phase III study (Table 3).43 Patients received four 6-week 
induction cycles (bortezomib 1.3 mg/m2 on days 1, 4, 8, 11, 
22, 25, 29, 32) followed by ﬁ  ve 6-week maintenance cycles 
Table 2 Grade 3 and greater hematologic side effects, and incidence of deep venous thromboembolism and peripheral neuropathy 
of thalidomide in MM
Trial Trial N Thrombocytopenia 
(%)
Neutropenia 
(%)
Infection 
(%)
DVT 
(%)
Peripheral neuropathy 
(%)
GIMEMA18 MPT 129 3 16 10 12 8
IFM 99-0619 MPT 125 14 48 13 12 6
IFM 01-01*21 MPT 113 ND 0 ND 7 2
Notes: *Grades 2 to 4; †Leukopenia.
Abbreviations: N, number of patients; ND, not determined.Biologics: Targets & Therapy 2009:3 103
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(bortezomib 1.3 mg/m2 on days 1, 8, 22, 29) in combination 
with oral melphalan 9 mg/m2 and prednisone 60 mg/m2/day. 
The primary endpoint was time to progression. MPV was 
found signiﬁ  cantly superior to MP for all efﬁ  cacy endpoints: 
time to progression, progression-free survival, overall 
survival, time to next treatment, CR rate. An unprecedented 
30% CR rate was noted in patients receiving MPV. Time to 
progression was 24 months in the MPV group. After a median 
follow-up of 16.3 months, median survival was signiﬁ  cantly 
superior in the MPV group. The survival advantage was dem-
onstrated in patients younger and older than 75 years of age. 
Serious adverse events were noted in 46% and 36% of patients 
in MPV and MP, respectively. Most divergent grade 3/4 
toxicities between MPV and MP were gastrointestinal (20% in 
MPV versus 6% in MP), fatigue and asthenia (15% versus 
5%), and peripheral neuropathy (14% versus 0%). Peripheral 
neuropathy resolved or improved in 75% of cases in a median 
of approximately 60 days. Thrombosis/embolism was very 
low and the same on both arms (1%). Overall, these results 
clearly established MPV as a new standard of care for MM 
patients not eligible for ASCT.
MP + lenalidomide (Revlimid®)
Another successfully applied strategy has been the 
development of thalidomide derivatives potentially 
more potent compared to the parent compound and have 
fewer side-effects. Lenalidomide (Revlimid)® is a novel 
immunomodulatory agent that has shown activity both 
preclinically and clinically,44 alone or in combination with 
dexamethasone.45–47 Results from a phase I/II dose-escalating 
study of MP with lenalidomide (MPR) have been recently 
reported.48 Fifty-four patients were enrolled in the study. The 
median age of patients was 71 years (range 57–77 years). 
Patients received 9 cycles of lenalidomide (5–10 mg/daily, 
days 1–21) plus melphalan (0.18–0.25 mg/kg/day, days 
1–4) and prednisone 2 mg/kg/day every 4–6 weeks, 
followed by maintenance therapy with lenalidomide alone 
(10 mg/daily, days 1–21, every month). The maximum 
tolerated dose was lenalidomide 10 mg/daily for 21 days 
and melphalan 0.18 mg/kg for 4 days every 4–6 weeks. At 
this dose level, the overall response rate was 81% including 
48% of patients with at least a very good partial remission 
(VGPR;   90% response rate) and 24% of patients with 
immunoﬁ  xation-negative CR. The 1-year event-free survival 
and overall survival rates were 92% and 100%, respectively. 
The most common grade 3/4 adverse events were neutro-
penia and thrombocytopenia (52% and 24%, respectively 
at the maximum tolerated dose), febrile neutropenia (9%), 
vasculitis (9%), and thrombosis/embolism (5%). More than 
40% of patients required growth factor support. Overall, MPR 
was considered a promising ﬁ  rst-line treatment for elderly 
patients with an acceptable and manageable toxicity. These 
results formed the basis for the ongoing European Myeloma 
Network phase III study comparing MP with MPR, with or 
without lenalidomide maintenance.
Dexamethasone-based 
combinations
Glucocorticoids have significant activity in MM, in 
relapsed/refractory disease and in newly diagnosed 
disease. In a study of 112 patients with untreated MM, 
the response rate with dexamethasone alone was 43%.14 
In the 1990s, dexamethasone was considered a simple, 
effective, and safe primary treatment for a large fraction 
of patients, mainly in North America. In the course of 
time, high-dose dexamethasone was recognized as a major 
source of concern and disability for patients, especially in 
the elderly. An important contribution in that ﬁ  eld was the 
IFM study IFM 95 for newly diagnosed myeloma patients 
aged 65–75 years. In this study, 488 patients were randomly 
allocated to receive MP, melphalan with dexametha-
sone (M-Dex), dexamethasone alone, or dexamethasone 
with interferon alpha (Dex-IFN) (12). Patients receiving 
melphalan experienced a longer progression-free survival 
than those receiving dexamethasone-based regimens, but 
without any survival beneﬁ  t. In addition, all high-dose 
dexamethasone-based regimens were associated with a 
greater risk of severe toxicities, including severe pyogenic 
infections in the M-Dex arm, and gastrointestinal, diabetic 
and psychiatric complications in all dexamethasone-based 
regimens. When combining all severe nonhematological 
complications, the incidence was signiﬁ  cantly lower in 
Table 3 Comparative response and survival in MPV compared with MP
Trial Regimen N CR (%)  PR (%) TTP (mo) OS (mo)
VISTA43 MPV 344 30 82 24 82.6% (2 yr)
MP 338 5 50 16.6 69.5% (2 yr)
Abbreviations: N, number of patients; CR, complete response; PR, partial response; OS, overall survival; TTP, time to progression.Biologics: Targets & Therapy 2009:3 104
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the MP group (16%) than in the dexamethasone-containing 
groups (28%). Other study has demonstrated the higher 
incidence of adverse events in the MD arm.15
In a recent study from ECOG (Eastern Cooperative 
Oncology Group) comparing thalidomide plus dexamethasone 
(Thal/Dex) with dexamethasone alone in newly diagnosed 
patients, and even though the treatment duration was short and 
the study population included some young patients (median age 
65 years, range 38–82), grade 3 or higher nonhematological 
toxicities were seen with 43% of patients with dexamethasone 
alone, and grade 3 or higher hyperglycemia, fatigue, insomnia, 
and muscle weakness were noted in 15%, 10%, 5%, and 9% of 
patients, respectively.49 Toxicity of any type grade 4 or 5 was 
observed in 18% of patients including 4% treatment-related 
deaths. In addition, many other patients suffered from grade I/II 
dexamethasone-related toxicities which were also a source 
of disability. The toxicity of the Thal/Dex combination was 
higher than that observed with dexamethasone alone. Grade 3 
or higher nonhematological toxicities were seen with 67% of 
patients within four cycles. Grade 4 or higher nonhematologic 
toxicities were seen with 35% of patients and treatment-related 
deaths in 5%.
A conﬁ  rmation of this signiﬁ  cant toxicity was recently 
provided by the Central European Myeloma Study Group 
phase III study in elderly patients (289 patients; median 
age: 72 years) comparing Thal/Dex with MP. The study 
reported higher complete and near CR rates (30% vs 14%) 
for patients receiving Thal/Dex.50 Progression-free 
survival was similar in both groups (median 20.7 and 
16.7 months for MP and Thal/Dex, respectively) but 
signiﬁ  cantly shorter overall survival was observed in the 
Thal/Dex group (median 49.4 and 41.5 months for MP 
and Thal/Dex, respectively). The population was very 
elderly; especially in the Thal/Dex group with 60% of 
patients between the ages 70 and 79 and 10% ≥80 years. 
Patients received a high-dose dexamethasone regimen 
and thalidomide dosing was, up to 400 mg/daily. Thus, 
the very elderly patient population and the higher doses 
of thalidomide and dexamethasone used likely con-
tributed to a higher mortality rate in Thal/Dex-treated 
patients during the first year of study, especially in 
patients with a poorer performance status. When taken 
together with the MPT results from the Nordic Myeloma 
Study Group trial, these ﬁ  ndings suggest that treatment 
with new drug combinations should be very carefully 
monitored in elderly patients, especially those over 
75 years of age. Anthracyclins or alkylating agents 
have also been incorporated into the Thal/Dex regimen.51 
The cyclophosphamide – thalidomide – dexamethasone 
(CTD) combination has proved to be effective in 
relapsed patients.52 These promising results prompted 
the Medical Research Council to proceed with a large 
phase III randomized study (MRC IX) comparing, in 
patients ineligible for transplantation, MP to CTD with an 
attenuated dexamethasone dose. Results from that study 
are eagerly anticipated.
Overall, when considering all these Thal/Dex experiences 
in terms of both efﬁ  cacy and toxicity, there is evidence that 
this combination is inferior to MPT and may not be optimal 
for elderly patients.
Along with the frequent and serious dexamethasone 
side-effects, there were also data suggesting that high-doses 
of dexamethasone were possibly not necessary in combination 
with novel agents, such as thalidomide or lenalidomide.53,54 
The ECOG group proceeded recently with a study (ECOG 
E4A03) comparing lenalidomide plus high-dose dexametha-
sone (40 mg daily, days 1–4, 9–12, 17–20) with lenalidomide 
plus low-dose dexamethasone (40 mg daily, days 1, 8, 15, 
22).55 445 patients, median age 66 years (up to 88 years), were 
treated, including 233 over the age of 65 years. The signiﬁ  cant 
toxicity of the high-dose dexamethasone regimen was fully 
conﬁ  rmed but the good news was the modest toxicity of the 
low-dose dexamethasone regimen. Infection/pneumonia, 
fatigue, hyperglycemia, deep venous thrombosis, and cardiac 
ischemia were signiﬁ  cantly less frequent with the low-dose 
dexamethasone schedule. Overall, nonhematologic toxicity 
of any type grade ≥3 or higher was found in 52% of patients 
receiving lenalidomide plus high-dose dexamethasone com-
pared to 34% of patients receiving lenalidomide plus low-dose 
dexamethasone. Early deaths were also signiﬁ  cantly less 
frequent in the low-dose dexamethasone arm; 1.4%, versus 
4.5%. The two-year survival was superior in the group of 
patients receiving the low-dose dexamethasone regimen 
(87% versus 75%), including in the subgroup of patients aged 
over 65 years (82% versus 67%). Of note, the excess mortality 
in the high-dose dexamethasone arm was due to both disease 
progressive as well as increased toxicity. Overall, and even 
though the study was not designed to test efﬁ  cacy of long-
term lenalidomide plus dexamethasone (median durations 
on treatment were only 4 months in the high-dose dexa-
methasone arm and 6 months in the low-dose dexamethasone 
arm), lenalidomide and low-dose dexamethasone was found 
highly active in newly diagnosed elderly patients. There is 
no doubt that these results will be of major importance in the 
future and will inﬂ  uence the fate of all dexamethasone-based 
combinations.Biologics: Targets & Therapy 2009:3 105
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Maintenance therapy in MM (Table 4)
In the pre-thalidomide era, maintenance therapy56 with 
alkylating agents had failed to demonstrate any beneﬁ  t57,58 as 
well as interferon which showed a modest increase in progres-
sion free survival and a minimal beneﬁ  t in overall survival.59,60 
Corticosteroid maintenance was found to prolong the duration 
of response but the effect on survival was controversial.61,62 
Four randomized phase III trials evaluated the beneﬁ  t of tha-
lidomide maintenance after ASCT,63–66 and found thalidomide 
maintenance an effective approach following autologous 
stem cell transplantation in young patients (Table 4). Two 
ongoing studies are furthermore evaluating maintenance by 
thalidomide, the SouthWest Oncology Group, SWOG 0204 
study67 and the HOVON-50/GMM-HD3 large trial,68 with 
only preliminary data available. Unfortunately, no large ran-
domized study has looked so far speciﬁ  cally at older patients. 
In the near future, results from the MRC IX trial, which has 
included maintenance study comparing thalidomide versus 
observation-only, will be available. Several trials are also 
ongoing with lenalidomide maintenance.
Supportive care therapy
In symptomatic multiple myeloma, especially in elderly 
patients, most commonly experienced complications 
are asthenia, anorexia, and severe bone pain. Focal or 
diffuse bone involvement represents a common and 
disabling event in multiple myeloma. At diagnosis, bone 
pain in the skeleton, and particularly in the lumbar spine, 
represents the predominant symptom, 70% of patients, 
and is also a common indicator of relapse or progres-
sive disease. In addition bone involvement contributes, 
along with immobility, dehydration and impaired renal 
calcium excretion, to the development of hypercalcemia. 
Anemia occurs in 30% to 62% of patients with multiple 
myeloma, particularly in those with advanced disease or 
delayed diagnosis, where it also has prognostic relevance.69 
Infections are frequent complications of multiple myeloma 
and the most common causes of death due to suppression 
of production of polyclonal immunoglobulins, of decreased 
T-cell function and neutropenia. Such complications are a 
major cause of morbidity and mortality in myeloma patients, 
especially in elderly patients. Supportive care is therefore of 
critical importance in the treatment of elderly myeloma, in 
parallel with the speciﬁ  c treatment of myeloma.
Skeletal-related complications
Bone destruction in multiple myeloma (pathologic fractures, 
spinal cord compression, hypercalcemia) is a major cause 
of morbidity and signiﬁ  cantly decrease quality of life, cause 
severe pain from bone lesions and neurological impairments. 
Although microfractures and pathologic fractures are common 
clinical manifestations in patients with multiple myeloma, 
they are rather infrequent. Pathologic fractures are usually site 
skeletal-related, with the majority involving vertebras (55% 
to 70%), lumbar and thoracic predominantly.4 Although bone 
destruction in elderly myeloma is not different from younger 
patients, the diagnosis of bone lesions related to myeloma might 
be difﬁ  cult in elderly patients in the context of osteoporosis.6
The bone lesions-related pain described by patients 
with myeloma required speciﬁ  c treatment with effective 
analgesia. An effective analgesia is recommended using the 
WHO pain ladder to scale pain description from patients. 
Sufﬁ  cient dosing and adequate scheduling of pain treatment 
are essential in order to ascertain sufﬁ  cient and continuous 
pain control. Radiotherapy is also indicated for painful 
lesions: most patients signiﬁ  cantly achieve pain relief with 
local radiotherapy at a dose of 30 grays in 10 to 15 fractions. 
Other indications include the treatment of impending or 
actual pathologic fractures, spinal cord compression, tumor 
causing local neurological problems, and large soft tissue 
plasma cell tumors. Radiotherapy has also been shown 
to prevent the development of new vertebral fractures.70 
Table 4 Maintenance treatment with thalidomide
Authors N. of patients Duration 
of treatment
N. of 
ASCT
CR rate 
(%)
PFS 
(%)
OS 
(%)
Barlogie et al63 668 Onset until 
relapse or 
toxicity
double 65 vs 43 56 vs 44 (5-year) 65 vs 65 (5-year)
IFM 99-0264 597 Until relapse 
or toxicity
double 67 vs 57 52 vs 36 or 37(3-year) 87 vs 74 or 77 (4-year)
Australian Study65 243 12 months single 24 vs 15 63 vs 36 (2-year) 51 vs 80 (2-year)
Tunisian Study66 140 6 months single 67 vs 51 85 vs 57 85 vs 65
Abbreviations: N., number; CR, complete response; PFS, progression-free survival; OS, overall survival; VS, versus.Biologics: Targets & Therapy 2009:3 106
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Surgical intervention may be required in patients with an 
impending or actual fracture or a spinal compression.71 
Most patients also require radiotherapy in conjunction with 
surgery. Recent development of minimally invasive surgical 
procedures, such as vertebroplasty and kyphoplasty, allows 
myeloma patients with vertebral compression fractures to 
have immediate improvement in quality of life and shorter 
inpatient duration.72
Novel therapeutic approach for bone disease in multiple 
myeloma is represented by bisphosphonates which are derived 
from pyrophosphates by substitution of an oxygen atom with 
a carbon atom which confers a resistance to the activity of 
phosphatases in vivo, thus allowing prolonged inhibition of 
bone resorption.73,74 Bisphosphonates inhibit the recruitment 
of osteoclasts from their precursor cells and suppress their 
subsequent cellular proliferation and differentiation. They also 
bind to bone surfaces, thus protecting them from destruction, 
inhibit production of IL6, the most important growth hormone 
for myeloma cells, and stimulate apoptosis of osteoclasts 
and myeloma cells. The efﬁ  cacy of the bisphosphonates 
clodronate, pamidronate, and zoledronate in preventing 
bone lesions has been investigated in several randomized 
trials: bisphosphonates decrease episodes of hypercalcemia, 
height loss, vertebral fractures, the development of new lytic 
lesions and pain.75,76 The addition of high potency intravenous 
bisphosphonates to myeloma therapy has provided major 
symptomatic beneﬁ  ts to patients with multiple myeloma.77 
They also decrease the need for palliative radiation and 
recently presented data suggested that they may prolong time 
to disease progression.78
Osteonecrosis of the jaw (ONJ) is a major oral complication 
in patients with multiple myeloma secondary to intravenous 
bisphosphonates use79–81 Intravenous bisphosphonates 
that contain an amino terminal group (pamidronate) or a 
nitrogen-containing side group (zoledronic acid) seem to 
present the highest risk for development of this phenomenon. 
Bisphosphonate-induced ONJ has been documented in both 
the maxilla and mandible, although there is a higher rate 
of incidence reported in the mandible. The median time to 
onset of ONJ among patients receiving zoledronic acid was 
18 months and 3 to 6 years for patients receiving pamidronate. 
It is recommended that patients with multiple myeloma, who 
are being considered for IV bisphosphonates therapy, undergo 
a dental examination that includes clinical and radiographic 
evaluations. Any tooth or periodontal diseases should be 
appropriately controlled before initiation of IV bisphospho-
nates therapy. Dental extractions and other procedures that 
expose or manipulate bone should be avoided in these patients. 
Due to the increasing risk of ONJ with duration of therapy, 
bisphosphonates should be discontinued after a maximum of 
2 years of therapy in patients who have achieved CR and/or 
plateau phase. For patients whose disease is active, who 
have not achieved response, or who have a threatening bone 
disease beyond 2 years, therapy can be use to a dose every 
3 months.82,83
Anemia
In general, anemia of multiple myeloma is normochomic, 
normo-macrocytic and especially at the disease onset, is 
often moderate and well-tolerated. In about 5% of the patients 
anemia may be the sole sign of the disease. The pathogenesis 
of anemia in multiple myeloma is multifactorial and 
causes vary with the phase of the disease. Plasma cell bone 
marrow inﬁ  ltration represents the most important cause at 
diagnosis. However, other causes are hemodilution due 
to hypervolemia, reduced survival of erythrocytes, poor 
utilization of circulating iron, and renal failure. In addition, 
myeloma therapy, either chemotherapy or radiotherapy, may 
induce or worsen anemia. The role of a blunted production of 
endogenous erythropoietin (EPO) in anemia of MM patients 
has been demonstrated.69 In particular, reduced synthesis of 
EPO has been documented not only in MM subjects with 
renal failure (25%), but also in patients with normal renal 
function. Cytokines such as IL-1β and tumor necrosis factor, 
produced by normal and neoplastic cells in MM, could inhibit 
the renal production of EPO while the role of the IL-6 is not 
clear in this context.
Several clinical trials have investigated the effects 
of recombinant EPO(r-EPO) in myeloma patients suffering 
from anemia.69 These studies indicate that r-EPO is an 
effective and safe drug for treating anemia of multiple 
myeloma. Quality of life in responding patients signiﬁ  -
cantly improves with hemoglobin increment and transfusion 
independency. A functional or relative iron deﬁ  ciency might 
occur in some patients during r-EPO treatment, and iron 
supplementation might be required to respond to r-EPO 
therapy.84,85 Thromboembolic complications are the most 
important adverse event of EPO treatment. The risk is higher 
in patients with multiple myeloma treated with thalidomide 
or lenalidomide.86 Prophylactic anticoagulation with 
low-molecular-weight heparin or aspirin is recommended 
in these treatments.87
Infections
In early-stage myeloma, the most common infections 
are bronchitis and pneumonia, predominantly caused by Biologics: Targets & Therapy 2009:3 107
Treatment of elderly multiple myeloma
Haemophilus influenzae and Streptococcus pneumoniae. 
In patients with advanced myeloma and during the neutropenic 
phases of chemotherapy, S. aureus and Gram-negative bacteria 
are more common. Treatment is based on antibiotics.6 Vaccina-
tion against H. inﬂ  uenzae and S. pneumoniae is recommended, 
with 61% of patients producing protective antibodies against 
pneumococci and 75% against H. inﬂ  uenzae. A randomized 
trial showed that prophylaxis of infection with monthly 
immunoglobulin infusions (0.4 g/kg) for a period of one year 
signiﬁ  cantly reduced the frequency and severity of infec-
tions with patients who responded poorly to pneumococcal 
immunization.
Conclusion
Large randomized phase III studies have now established 
MPT and MPV as new standards of care for a large proportion 
of elderly MM patients ineligible for ASCT. MPR may also 
provide a survival advantage over MP. This potentially may 
lead to the availability of three therapeutic options for the 
treatment of newly diagnosed elderly patients with MM. 
These options could lead to more personalized treatment 
approaches, based on patient comorbidities, as the three novel 
agents have somewhat different toxicity proﬁ  les. Physicians 
should also keep in mind that an adequate symptomatic treat-
ment remains essential as well as a very careful treatment 
monitoring. The dexamethasone history, and also some recent 
experiences with new drugs have shown that the highest 
doses of drugs are not always optimal in elderly patients. All 
efforts should be made to avoid excessive toxicity, particu-
larly in patients with initial bad performance status, and early 
phases of treatment are critical. Outpatient administration of 
drugs and patient quality of life should also be favored.
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